<?xml version='1.0' encoding='utf-8'?>
<document id="23873286"><sentence text="Assessment of CYP3A-mediated drug-drug interaction potential for victim drugs using an in vivo rat model." /><sentence text="The present study aims to determine if an in vivo rat model of drug-drug interaction (DDI) could be useful to discriminate a sensitive (buspirone) from a 'non-sensitive' (verapamil) CYP3A substrate, using ketoconazole and ritonavir as perpetrator drugs"><entity charOffset="136-145" id="DDI-PubMed.23873286.s2.e0" text="buspirone" /><entity charOffset="205-217" id="DDI-PubMed.23873286.s2.e1" text="ketoconazole" /><entity charOffset="222-231" id="DDI-PubMed.23873286.s2.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.23873286.s2.e0" e2="DDI-PubMed.23873286.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23873286.s2.e0" e2="DDI-PubMed.23873286.s2.e1" /><pair ddi="false" e1="DDI-PubMed.23873286.s2.e0" e2="DDI-PubMed.23873286.s2.e2" /><pair ddi="false" e1="DDI-PubMed.23873286.s2.e1" e2="DDI-PubMed.23873286.s2.e1" /><pair ddi="false" e1="DDI-PubMed.23873286.s2.e1" e2="DDI-PubMed.23873286.s2.e2" /></sentence><sentence text=" Prior to in vivo studies, ketoconazole and ritonavir were shown to inhibit midazolam hydroxylation with IC50 values of 350 ± 60 nm and 11 ± 3 nm, respectively, in rat liver microsomes (RLM)"><entity charOffset="27-39" id="DDI-PubMed.23873286.s3.e0" text="ketoconazole" /><entity charOffset="44-53" id="DDI-PubMed.23873286.s3.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.23873286.s3.e0" e2="DDI-PubMed.23873286.s3.e0" /><pair ddi="false" e1="DDI-PubMed.23873286.s3.e0" e2="DDI-PubMed.23873286.s3.e1" /></sentence><sentence text=" Buspirone and verapamil were also shown to be substrates of recombinant rat CYP3A1/3A2"><entity charOffset="1-10" id="DDI-PubMed.23873286.s4.e0" text="Buspirone" /><entity charOffset="15-24" id="DDI-PubMed.23873286.s4.e1" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.23873286.s4.e0" e2="DDI-PubMed.23873286.s4.e0" /><pair ddi="false" e1="DDI-PubMed.23873286.s4.e0" e2="DDI-PubMed.23873286.s4.e1" /></sentence><sentence text=" In the rat model, the mean plasma AUC0-inf of buspirone (10 mg/kg, p"><entity charOffset="47-56" id="DDI-PubMed.23873286.s5.e0" text="buspirone" /></sentence><sentence text="o" /><sentence text=") was increased by 7" /><sentence text="4-fold and 12" /><sentence text="8-fold after co-administration with ketoconazole and ritonavir (20 mg/kg, p"><entity charOffset="36-48" id="DDI-PubMed.23873286.s9.e0" text="ketoconazole" /><entity charOffset="53-62" id="DDI-PubMed.23873286.s9.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.23873286.s9.e0" e2="DDI-PubMed.23873286.s9.e0" /><pair ddi="false" e1="DDI-PubMed.23873286.s9.e0" e2="DDI-PubMed.23873286.s9.e1" /></sentence><sentence text="o" /><sentence text="), respectively" /><sentence text=" The mean plasma AUC0-inf of verapamil (10 mg/kg, p"><entity charOffset="29-38" id="DDI-PubMed.23873286.s12.e0" text="verapamil" /></sentence><sentence text="o" /><sentence text=") was increased by 3" /><sentence text="0-fold and 4" /><sentence text="8-fold after co-administration with ketoconazole and ritonavir (20 mg/kg, p"><entity charOffset="36-48" id="DDI-PubMed.23873286.s16.e0" text="ketoconazole" /><entity charOffset="53-62" id="DDI-PubMed.23873286.s16.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.23873286.s16.e0" e2="DDI-PubMed.23873286.s16.e0" /><pair ddi="false" e1="DDI-PubMed.23873286.s16.e0" e2="DDI-PubMed.23873286.s16.e1" /></sentence><sentence text="o" /><sentence text="), respectively" /><sentence text=" Thus, the rat DDI model correctly identified buspirone as a sensitive CYP3A substrate (&gt;5-fold AUC change) in contrast to verapamil"><entity charOffset="46-55" id="DDI-PubMed.23873286.s19.e0" text="buspirone" /></sentence><sentence text=" In addition, for both victim drugs, the extent of DDI when co-administered was greater with ritonavir compared with ketoconazole, in line with their in vitro CYP3A inhibition potency in RLM"><entity charOffset="93-102" id="DDI-PubMed.23873286.s20.e0" text="ritonavir" /><entity charOffset="117-129" id="DDI-PubMed.23873286.s20.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.23873286.s20.e0" e2="DDI-PubMed.23873286.s20.e0" /><pair ddi="false" e1="DDI-PubMed.23873286.s20.e0" e2="DDI-PubMed.23873286.s20.e1" /></sentence><sentence text=" In conclusion, our study extended the rat DDI model applicability to two additional victim/perpetrator pairs" /><sentence text=" In addition, we suggest that use of this model would increase our confidence in estimation of the DDI potential for victim drugs in early discovery" /><sentence text="" /></document>